Ansell SM - Search Results

1

Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients.

Rossille D, Azzaoui I, Feldman AL, Maurer MJ, Labouré G, Parrens M, Pangault C, Habermann TM, Ansell SM, Link BK, Tarte K, Witzig TE, Lamy T, Slager SL, Roussel M, Milpied N, Cerhan JR, Fest T. Rossille D, et al. Among authors: ansell sm. Leukemia. 2017 Apr;31(4):988-991. doi: 10.1038/leu.2016.385. Epub 2017 Jan 27. Leukemia. 2017. PMID: 28035137 Free PMC article. No abstract available.

2

Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma.

Ansell SM, Habermann TM, Kurtin PJ, Witzig TE, Chen MG, Li CY, Inwards DJ, Colgan JP. Ansell SM, et al. J Clin Oncol. 1997 Jun;15(6):2296-301. doi: 10.1200/JCO.1997.15.6.2296. J Clin Oncol. 1997. PMID: 9196143

3

Primary laryngeal lymphoma.

Ansell SM, Habermann TM, Hoyer JD, Strickler JG, Chen MG, McDonald TJ. Ansell SM, et al. Laryngoscope. 1997 Nov;107(11 Pt 1):1502-6. doi: 10.1097/00005537-199711000-00014. Laryngoscope. 1997. PMID: 9369397

4

Primary thyroid lymphoma.

Ansell SM, Grant CS, Habermann TM. Ansell SM, et al. Semin Oncol. 1999 Jun;26(3):316-23. Semin Oncol. 1999. PMID: 10375088 Review.

5

Evaluation of the proliferative index as a prognostic factor in diffuse large cell lymphoma: correlation with the International Index.

Ansell SM, Kurtin PJ, Stenson M, Habermann TM, Greipp PR, Therneau TM, Witzig TE. Ansell SM, et al. Leuk Lymphoma. 1999 Aug;34(5-6):529-37. doi: 10.3109/10428199909058480. Leuk Lymphoma. 1999. PMID: 10492076

6

Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.

Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. Ansell SM, et al. J Clin Oncol. 2001 Feb 1;19(3):720-6. doi: 10.1200/JCO.2001.19.3.720. J Clin Oncol. 2001. PMID: 11157023

7

Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis.

Kanelli S, Ansell SM, Habermann TM, Inwards DJ, Tuinstra N, Witzig TE. Kanelli S, et al. Among authors: ansell sm. Leuk Lymphoma. 2001 Nov-Dec;42(6):1329-37. doi: 10.3109/10428190109097760. Leuk Lymphoma. 2001. PMID: 11911416 Clinical Trial.

8

Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells.

Arendt BK, Velazquez-Dones A, Tschumper RC, Howell KG, Ansell SM, Witzig TE, Jelinek DF. Arendt BK, et al. Among authors: ansell sm. Leukemia. 2002 Oct;16(10):2142-7. doi: 10.1038/sj.leu.2402714. Leukemia. 2002. PMID: 12357369

9

Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia.

Cerhan JR, Vachon CM, Habermann TM, Ansell SM, Witzig TE, Kurtin PJ, Janney CA, Zheng W, Potter JD, Sellers TA, Folsom AR. Cerhan JR, et al. Among authors: ansell sm. Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1466-71. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12433728

10

Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma.

Ansell SM, Arendt BK, Grote DM, Jelinek DF, Novak AJ, Wellik LE, Remstein ED, Bennett CF, Fielding A. Ansell SM, et al. Leukemia. 2004 Mar;18(3):616-23. doi: 10.1038/sj.leu.2403281. Leukemia. 2004. PMID: 14749704

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

588 results

Search Page

Filters